In plain terms: Semaglutide has strong evidence from human clinical trials. The benefit shown in those trials is reduction of major adverse cardiovascular events, in two separate randomized populations. weight loss is the reason most people take it and is not the endpoint that earns the a if that describes your situation.
Semaglutide
The evidence as the record states it
Lincoff et al., SELECT (New England Journal of Medicine, 2023; PMID 37952131): 17,604 adults aged 45 and over with pre-existing cardiovascular disease and BMI 27 or higher, without diabetes, randomized to semaglutide 2.4 mg weekly or placebo. Pre-specified primary composite of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke: 6.5% versus 8.0%, hazard ratio 0.80 (95% CI 0.72 to 0.90, p<0.001), over a mean 39.8 months. Permanent discontinuation for adverse events was 16.6% versus 8.2%. Marso et al., SUSTAIN-6 (New England Journal of Medicine, 2016; PMID 27633186): 3,297 adults with type 2 diabetes, same composite endpoint, 6.6% versus 8.9%, hazard ratio 0.74 (95% CI 0.58 to 0.95). Two independent randomized trials in different populations, both on a hard clinical outcome. Grade A is reached by a replicated hard clinical outcome, a replicated objectively measured function, or a replicated scale scored by a clinician blinded to treatment; this record takes the first route. Wilding et al., STEP-1 (New England Journal of Medicine, 2021; PMID 33567185) is cited for the weight endpoint and is not what the A rests on. Retinopathy complications were more frequent on semaglutide in SUSTAIN-6.
Why Grade A and not higher
Grade A requires a hard clinical endpoint or objectively measured functional outcome, independently replicated across at least two trials. Semaglutide meets that standard based on the trials cited above. A downgrade to Grade B would follow if replication attempts produced null results, if the effect size proved substantially smaller in a broader population, or if the studied dose proved impractical to sustain.
What this grade covers and what it does not
What would move this grade
A null result in a well-powered independent replication trial, or evidence that the effect does not hold at a practically sustainable dose, would prompt downgrade to Grade B.
How this was studied
Form: Semaglutide by subcutaneous injection once a week, added to standard care, versus placebo · Dose: 0.5 mg or 1.0 mg weekly (SUSTAIN-6); 2.4 mg weekly (SELECT) · Population: 3,297 adults with type 2 diabetes at high cardiovascular risk, 83 percent with established cardiovascular disease, chronic kidney disease or both (SUSTAIN-6); 17,604 adults aged 45 or older with established cardiovascular disease and a BMI of 27 or more, without diabetes (SELECT) · Duration: 104 weeks (SUSTAIN-6); mean follow-up 39.8 months (SELECT) · What is sold differs: The trials this grade rests on used the weekly injection; the daily tablet is a different route and dose. Every participant had type 2 diabetes or established cardiovascular disease, so the grade does not describe use in healthy adults.